CervoMed Inc. (NASDAQ: CRVO) announced that initial biomarker results from its Phase 2a clinical trial of neflamapimod in nonfluent variant ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE